Newsroom

ANAHEIM, Calif.--(BUSINESS WIRE)--Certerra, a leading provider of technology-enabled testing, inspection, and certification services for critical infrastructure and industrial markets, announced that Code NDT has joined the Certerra platform and will operate as part of the company’s Southwest Division.The addition of Code NDT strengthens Certerra’s non-destructive testing (NDT) capabilities across the Southwest and supports the company’s continued expansion of specialized inspection services ser...

SAN FRANCISCO--(BUSINESS WIRE)--ComplianceCow, an agentic automation platform for enterprise security GRC teams, will host a live webinar on June 22, 2026 demonstrating how Generative AI transforms natural language inputs into deterministic, auditable Continuous Controls Monitoring (CCM) 3.0 controls inside ServiceNow IRM. The session, titled From Prompt to Production: Building Automated CCM 3.0 Controls with Generative AI in ServiceNow IRM, runs from 1:30 to 2:00 pm ET and is open to complianc...

DENVER--(BUSINESS WIRE)--CCS Facility Services has expanded into Ohio, its fourteenth state, strengthening its Midwest presence....

TAMPA, Fla.--(BUSINESS WIRE)--XTIUM, a global managed services provider delivering secure digital workplaces, managed security, cloud, network, and unified communications solutions, today launched XTAI — XTIUM Trusted AI, its integrated AI services solution, establishing the company as the premier AI MSP for mid-market and enterprise organizations globally. XTIUM carefully crafted its AI program based on its 25-year history of providing IT excellence in Managed Networks, Voice, Cloud, Security,...

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to Jimmy John’s Funding, LLC Series 2026-1 Class A-1 VFN and Class A-2 Notes, a whole business securitization (WBS). The rating actions follow KBRA’s analysis which indicates that existing credit enhancement for the notes and cash flows are sufficient to support the ratings following the issuance of the Series 2026- 1. In conjunction with the issuance of the Series 2026-1 Notes, the Series 2017-1 Class A-2-II, Series 2022-1 Class A-1,...

SANTA ROSA, Calif.--(BUSINESS WIRE)--The collaboration gives customers access to Keysight Eggplant Test, an AI-driven test automation solution to validate their digital engineering....

SAN FRANCISCO--(BUSINESS WIRE)--Encore Consumer Capital, LP (“Encore”), a private equity firm that invests exclusively in food and consumer products, is pleased to announce the sale of substantially all of the equity of TP Parent LLC (“Twang Foodservice”) to Solina USA Inc. (“Solina”), the US division of a leading European custom ingredient manufacturer. Twang Foodservice, based in San Antonio, Texas, is a manufacturer of customized beverage systems, dry beverage mixes, flavor concentrates, sea...

OAKVILLE, Ontario--(BUSINESS WIRE)--Harvest ETFs (“Harvest”) is pleased to announce that it has received the final prospectus notice from the securities regulators for the Harvest SpaceX Enhanced High Income Shares ETF (“SPXE”) dated June 10, 2026 and is expected to commence trading on the Toronto Stock Exchange (“TSX”) on Monday June 15, 2026 under the ticker symbol SPXE. SPXE provides single-stock ETF access to the growth potential of Space Exploration Technologies Corp. by engaging modest le...

OAKVILLE, Ontario--(BUSINESS WIRE)--Harvest ETFs (« Harvest ») a le plaisir d’annoncer qu’elle a reçu l’avis de prospectus final des autorités de réglementation des valeurs mobilières pour le FNB Harvest d’actions à revenu élevé amélioré SpaceX (« SPXE ») le 11 juin 2026 et qu’elle devrait commencer à être négociée à la Bourse de Toronto (« TSX ») le lundi 15 juin 2026 sous le symbole boursier SPXE. SPXE offre un accès FNB à action unique au potentiel de croissance Space Exploration Technologie...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE® FL-1 trial, evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, in combination with rituximab and lenalidomide (epcoritamab + R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), which showed that epcoritamab + R2 delivered consistent and sustained efficacy benefits across clinically relev...